Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC

JE Frampton - Targeted oncology, 2022 - Springer
Osimertinib (TAGRISSO®) is an orally administered, third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor that is approved for the adjuvant treatment of …
被引用次数：5 相关文章

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC

JE Frampton - Targeted Oncology, 2022 - search.proquest.com
Osimertinib (TAGRISSO®) is an orally administered, third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor that is approved for the adjuvant treatment of …

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.

JE Frampton - Targeted Oncology, 2022 - europepmc.org
Osimertinib (TAGRISSO®) is an orally administered, third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor that is approved for the adjuvant treatment of …

[引用][C] Osimertinib: a Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC

JE Frampton - Targeted oncology - cochranelibrary.com

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC

JE Frampton - Targeted oncology, 2022 - pubmed.ncbi.nlm.nih.gov
Osimertinib (TAGRISSO®) is an orally administered, third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor that is approved for the adjuvant treatment of …